IMPAACT Annual Meeting

Priorities for HIV Research, Moving Ahead Through Partnerships

Carl W. Dieffenbach, Ph.D.
Director, Division of AIDS

June 22, 2021
June 5, 1981

Pneumocystis Pneumonia – Los Angeles

July 3, 1981

Kaposi’s Sarcoma and Pneumocystis Pneumonia Among Homosexual Men – New York City and California
Unexplained Immunodeficiency and Opportunistic Infections in Infants – New York, New Jersey, California

Epidemiologic Notes and Reports Possible Transfusion-Associated Acquired Immune Deficiency Syndrome (AIDS) – California
Organization of the HIV-1 Virion

HIV Genomic Map

- gag
- pol
- vif
- vpu
- env
- nef
- U3 R U5
- LTR
- vpr
- rev
- tat
- tat
- rev
Advances in HIV/AIDS Science 1981-2021

- Treatment
- Prevention
- Pathogenesis
- Diagnosis
- Etiology
- Virology
- Natural History
- Epidemiology
- Vaccine Development
Advances in HIV/AIDS Science 1981-2021

- Treatment
- Prevention
- Pathogenesis
- Diagnosis
- Etiology
- Virology
- Natural History
- Epidemiology
- Vaccine Development
What Has Changed in the Last 10 Years?

- Better medications
- Understanding ART → U=U
- Choices for HIV prevention
- Hepatitis C medications
- New TB medications, shortened treatment regimens
- Progress on TB vaccines, chemoprophylaxis for PLWH
- Progress in development of pediatric formulations
  Dolutegravir, Raltegravir (INSTIs) and Etravirine (NNRTI)
FOR IMMEDIATE RELEASE
Monday, November 30, 2020

NIAID Announces Newly Funded HIV/AIDS Clinical Trials Networks

Awards Will Run Through 2027
NIH/NIAID/DAIDS Priorities

For IMPAACT, addressing the therapeutic needs across the life span with emphasis on key populations
The NIH Strategic Plan for HIV Research, Collaborations

- Reduce the Incidence of HIV Therapies (Vaccines with HVTN)
- Conduct Research Toward HIV Cure (Collaboratories, Therapeutic Vaccines and bNAbs, ACTG)
- Address Tb as the primary HIV-associated Co-infection Neurocognitive/neurological effects as the primary comorbidity
- Advance Cross-cutting Areas of Research relevant to the key populations

Cross-cutting Areas of Research:
- Basic Virology and Immunology
- Behavioral and Social Sciences
- Epidemiology
- Health Disparities
- Information Dissemination
- Implementation Science
- Research Training, Infrastructure, and Capacity Building
Select Ongoing/Planned IMPAACT Studies for ARV and TB Drugs

- Ongoing studies with planned/upcoming registrational filing:
  - IMPAACT 2014, 2017, 2019, 2032

- Registrational studies planned/in development:
  - IMPAACT 2023, 2029, 2036, 2034, others

- Non-registrational studies that will provide data to inform guidelines:
  - IMPAACT 2026, P1108, others

- Need to assess the timing of when to begin these. Need to get a sustainable cadence to the trials
Questions?